Showing 4741-4750 of 8849 results for "".
- Revision to Launch Intellishade TruPhysicalhttps://practicaldermatology.com/news/revision-to-launch-intellishade-truphysical/2457912/Revision Skincare will be launching Intellishade® TruPhysical™, formulated with a proprietary blend of over 20 age-defying ingredients. The four-in-one moisturizer helps to correct, protect, hydrate and shield skin for a brighter, smoother complexion. According to
- Meet TempSure™ Envi from Hologic's Cynosure Divisionhttps://practicaldermatology.com/news/meet-tempsure-envi-from-hologics-cynosure-division/2457915/Hologic's Cynosure division is launching TempSure™ Envi – an FDA-cleared advanced radiofrequency device. TempSure™ Envi heats the deep layers of skin to regenerate collagen and impro
- Research Elucidates LIGHT's Role in ADhttps://practicaldermatology.com/news/research-elucidates-lights-role-in-ad/2457919/LIGHT, a member of the tumor necrosis factor (TNF) super family, directly controls the hyperproliferation of keratinocytes as well as the expression of periostin, a protein that contributes to the clinical features of atopic dermatitis and other inflammatory skin diseases such as scleroderma, rep
- New Research Explains Why Women Who Have Been Pregnant Have Better Melanoma Outcomeshttps://practicaldermatology.com/news/new-research-explains-why-women-who-have-been-pregnant-have-better-melanoma-outcomes/2457922/For decades, research has associated female sex and a history of previous pregnancy with better outcomes after a melanoma diagnosis. Now, a research team from Perelman School of Medicine at the University of Pennsylvania says it may have determined the reason for the melanoma-protective effect.</
- FDA Accepts Ortho Dermatologics' Filing for IDP-121 Acne Treatment In Lotion Formhttps://practicaldermatology.com/news/fda-accepts-ortho-dermatologics-filing-for-idp-121-acne-treatment-in-lotion-form/2457925/The FDA has accepted Ortho Dermatologics' New Drug Application for IDP-121 (tretinoin 0.05%) lotion (Altreno) with a PDUFA action date of Aug. 27, 2018. If approved, Altreno will be the first tretinoin product in lotion form rather than a gel or cream.
- Scientific First: Researchers Grow Hairy Skin In A Dishhttps://practicaldermatology.com/news/scientific-first-researchers-grow-hairy-skin-in-a-dish/2457934/Indiana University School of Medicine researchers have successfully developed a method to grow hairy skin from mouse pluripotent stem cells—a discovery that could lead to new approaches to model disease and new therapies for the treatment of skin disorders and cancers. This res
- New AD Yardstick Highlights Treatment Advanceshttps://practicaldermatology.com/news/new-ad-yardstick-highlights-treatment-advances/2457933/Treatment for atopic dermatitis (AD) has changed a lot in the last few years, according to a new yardstick published in Annals of Allergy, Asthma and Immunology. “The Atopic Dermatitis Yardstick
- Jiangsu Hengrui Medicine and Arcutis Partner for Immune-Mediated Dermatology Therapy Using SHR0302https://practicaldermatology.com/news/jiangsu-hengrui-medicine-and-arcutis-partner-for-immune-mediated-dermatology-therapy-using-shr0302/2457936/Jiangsu Hengrui Medicine Co., Ltd., a fully integrated biopharmaceutical company based in Shanghai, and Arcutis, Inc., a biotechnology company based in Menlo Park, CA, entered into an exclusive option and license agreement for the development and commercialization of topical applications of Hengr
- Microarray Skin Patch May Help Solve Antibiotic Resistance Crisishttps://practicaldermatology.com/news/microarray-skin-patch-may-help-solve-antibiotic-resistance-crisis/2457939/Skin microarray patches that administer drugs directly into the bloodstream through thousands of individual “microneedles” may help solve the antibiotic resistance crisis. “One of the biggest problems is that the huge majority of the drugs are taken orally. This me
- BridgeBio Pharma Appoints Drs. Sanuj Ravindran and Eric Michael David as CEOs-in-Residence to Lead Dermatology and Gene Therapy Programshttps://practicaldermatology.com/news/bridgebio-pharma-appoints-drs-sanuj-ravindran-and-eric-michael-david-as-ceos-in-residence-to-lead-dermatology-and-gene-therapy-programs/2457942/BridgeBio Pharma, a clinical-stage biopharmaceutical company, today announced that it has strengthened its executive leadership team with two key hires who will join the company as CEOs-in-residence. Sanuj Ravindran, MD, will serve as CEO of PellePharm, Inc. and wil